Blockage of thrombospondin 4 secreted by spinal astrocytes may be a promising therapeutic target in the treatment of neuropathic pain
Neslihan Düzenli , Cenk Can , Aytül Önal
Exploration of Neuroprotective Therapy ›› 2022, Vol. 2 ›› Issue (5) : 226 -241.
Neuropathic pain (NP), which is difficult to treat, remains a heavy burden for both individuals and society. The efficacy of current treatments is insufficient. The pathophysiology of NP is still not fully elucidated, and there is a need to explore new therapeutic targets to develop more effective treatment strategies. Recent studies showed that thrombospondin 4 (TSP4) protein expression is increased in the spinal cord following nervous system injury and that blocking or inhibiting this increase improves NP. In this review, it has been aimed to present the evidence for the role of TSP4 in the mechanisms of NP development and to evaluate the therapeutic potential of TSP4 blockade in the treatment of NP.
Astrocyte / dorsal root ganglion / neuropathic pain / nerve injury / rodent / spinal cord / thrombospondin 4
| [1] |
|
| [2] |
Zilliox LA. Neuropathic Pain. Continuum (Minneap Minn). 2017;23:512-32. |
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
Luis MB, Liguori NF, López PA, Alonso R. SARS-CoV-2 RNA detection in cerebrospinal fluid: presentation of two cases and review of literature. Brain Behav Immun Health. 2021; 15: 100282. |
| [12] |
Novi G, Rossi T, Pedemonte E, Saitta L, Rolla C, Roccatagliata L, |
| [13] |
|
| [14] |
Attal N, Martinez V, Bouhassira D. Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Pain Rep. 2021; 6: e884. |
| [15] |
Schlereth T. Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology (deutsche Gesellschaft für Neurologie). Neurol Res Pract. 2020; 2: 16. |
| [16] |
|
| [17] |
NHS [Internet]. GGC chronic non malignant pain neuropathic pain guidelines. c2020 [cited 2022 Aug 9]. Available from: https://clinicalguidelines.nhsggc.org.uk/media/2568/chronic-nonmalignant-pain-202.pdf |
| [18] |
Neuropathic pain in adults: pharmacological management in non-specialist settings. NICE clinical guidelines, No. 173. London: National Institute for Health and Care Excellence (NICE); 2020. |
| [19] |
|
| [20] |
European Medicines Agency [Internet]. Guideline on the clinical development of medicinal products intended for the treatment of pain. c2016 [cited 2022 Aug 9]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-intended-treatment-pain-first-version_en.pdf |
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
Butler S, Eek D, Ring L, Gordon A, |
| [27] |
Freynhagen R, Baron R, Kawaguchi Y, Malik RA, Martire DL, Parsons B, |
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
Adams JC. Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol. 2001; 17: 25-51. |
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
Yamagata K. Astrocyte-induced synapse formation and ischemic stroke. J Neurosci Res. 2021; 99: 1401-13. |
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
Cheng C, |
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, |
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
Obata H, Sakurazawa S, Kimura M, |
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
/
| 〈 |
|
〉 |